Analyst firms · J.P. Morgan · CERE
J.P. Morgan CERE price target and rating history
Cerevel Therapeutics Holdings Inc. (CERE) · Health Care
J.P. Morgan rates Cerevel Therapeutics Holdings Inc. (CERE) Neutral with a $25 price target, as of its latest action on Nov 20, 2023. It has published 3 rating actions on CERE since January 2022, including 0 upgrades and 1 downgrade.
- Current rating
- Neutral
- Price target
- $25
- Median target, all firms
- Too few
- Actions on CERE
- 3
J.P. Morgan price target on CERE
Every J.P. Morgan rating on CERE
- Nov 20, 2023
- Mar 17, 2023
- Jan 5, 2022
Questions about J.P. Morgan and CERE
- What is J.P. Morgan's price target for CERE?
- J.P. Morgan's latest stated price target for Cerevel Therapeutics Holdings Inc. (CERE) is $25, from its action on Nov 20, 2023.
- What is J.P. Morgan's rating on CERE?
- J.P. Morgan rates CERE Neutral, a neutral rating, as of Nov 20, 2023.
- When did J.P. Morgan last change its view on CERE?
- On Nov 20, 2023, J.P. Morgan resumes coverage at Neutral, price target $25.
More CERE rating histories
All J.P. Morgan ratingsCERE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.